These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2481029)

  • 1. Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.
    Bickel WK; Bigelow GE; Preston KL; Liebson IA
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1053-63. PubMed ID: 2481029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
    Preston KL; Bigelow GE; Bickel W; Liebson IA
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
    Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL; Bigelow GE; Bickel WK; Liebson IA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports.
    Oliveto AH; Bickel WK; Hughes JR; Shea PJ; Higgins ST; Fenwick JW
    J Pharmacol Exp Ther; 1992 Jun; 261(3):885-94. PubMed ID: 1602393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of buprenorphine in a drug discrimination procedure in humans.
    Bigelow GE; Preston KL
    NIDA Res Monogr; 1992; 121():28-37. PubMed ID: 1406908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure.
    Oliveto AH; McCance-Katz E; Singha A; Hameedi F; Kosten TR
    Behav Pharmacol; 1998 May; 9(3):207-17. PubMed ID: 9832935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorazepam and pentobarbital drug discrimination in baboons: cross-drug generalization and interaction with Ro 15-1788.
    Ator NA; Griffiths RR
    J Pharmacol Exp Ther; 1983 Sep; 226(3):776-82. PubMed ID: 6136600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
    Negus SS; Mello NK; Portoghese PS; Lukas SE; Mendelson JH
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1245-56. PubMed ID: 7791097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discrimination analysis of midazolam under a three-lever procedure: I. Dose-dependent differences in generalization and antagonism.
    Sannerud CA; Ator NA
    J Pharmacol Exp Ther; 1995 Jan; 272(1):100-11. PubMed ID: 7815322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
    Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
    J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of pentazocine as a discriminative stimulus in the squirrel monkey.
    White JM; Holtzman SG
    J Pharmacol Exp Ther; 1982 Nov; 223(2):396-401. PubMed ID: 7131294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of diazepam in humans.
    Johanson CE
    J Pharmacol Exp Ther; 1991 May; 257(2):634-43. PubMed ID: 2033509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics.
    Ator NA; Griffiths RR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1442-57. PubMed ID: 9316858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers.
    Walker DJ; Zacny JP
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1454-64. PubMed ID: 10336539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.